BMO Capital analyst Evan David Seigerman maintains Novo Nordisk (NYSE:NVO) with a Outperform and maintains $163 price target.
BMO Capital Maintains Outperform on Novo Nordisk, Maintains $163 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.